Heterogeneous expression of CFTR in insulin-secreting β-cells of the normal human islet

• Published in: PloS one Vol. 15; no. 12; p. e0242749
• Main Authors: Di Fulvio, Mauricio, Bogdani, Marika, Velasco, Myrian, McMillen, Timothy S, Ridaura, Cecilia, Kelly, Lisa, Almutairi, Mohammed M, Kursan, Shams, Sajib, Abu A, Hiriart, Marcia, Aguilar-Bryan, Lydia
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 02.12.2020; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Animals; Antibodies; Antibodies - metabolism; Antigens - metabolism; Beta cells; Biology and Life Sciences; Cell Line; Conductance; Cystic fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator - immunology; Cystic Fibrosis Transmembrane Conductance Regulator - metabolism; Diabetes; Diabetes mellitus; Electrophysiology; Female; Humans; Immunofluorescence; Immunohistochemistry; Infant; Insulin; Insulin Secretion; Insulin-Secreting Cells - metabolism; Laboratories; Male; Medicine; Medicine and Health Sciences; Mice; Microscopy; Middle Aged; Morbidity; Mutation; Pancreas; Pathogenesis; Patients; Pharmacology; Physical Sciences; Pulmonary functions; Rats; Reproducibility of Results; Research and Analysis Methods; Respiratory function; Toxicology; Western blotting; Young Adult; United States > US; Mexico; Pacific Northwest
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0242749

Cystic fibrosis (CF) is due to mutations in the CF-transmembrane conductance regulator (CFTR) and CF-related diabetes (CFRD) is its most common co-morbidity, affecting ~50% of all CF patients, significantly influencing pulmonary function and longevity. Yet, the complex pathogenesis of CFRD remains unclear. Two non-mutually exclusive underlying mechanisms have been proposed in CFRD: i) damage of the endocrine cells secondary to the severe exocrine pancreatic pathology and ii) intrinsic β-cell impairment of the secretory response in combination with other factors. The later has proven difficult to determine due to low expression of CFTR in β-cells, which results in the general perception that this Cl-channel does not participate in the modulation of insulin secretion or the development of CFRD. The objective of the present work is to demonstrate CFTR expression at the molecular and functional levels in insulin-secreting β-cells in normal human islets, where it seems to play a role. Towards this end, we have used immunofluorescence confocal and immunofluorescence microscopy, immunohistochemistry, RT-qPCR, Western blotting, pharmacology, electrophysiology and insulin secretory studies in normal human, rat and mouse islets. Our results demonstrate heterogeneous CFTR expression in human, mouse and rat β-cells and provide evidence that pharmacological inhibition of CFTR influences basal and stimulated insulin secretion in normal mouse islets but not in islets lacking this channel, despite being detected by electrophysiological means in ~30% of β-cells. Therefore, our results demonstrate a potential role for CFTR in the pancreatic β-cell secretory response suggesting that intrinsic β-cell dysfunction may also participate in the pathogenesis of CFRD.